Target product profile creation Challenge A UK based privately-held biotechnology company developing and exploiting a proprietary technology platform for optimising and controlling gene therapy expression was looking to evolve its business model, including examining the potential for the company to build its own internal cell and gene therapy pipeline. The Board and investor had decided to prioritise review of an idea of exploitation of the company’s existing technology in developing a novel gene therapy for a rare cardiovascular condition. Alacrita was asked to develop an outline Target Product Profile (TPP) for a gene therapy for this particular condition. Solution Alacrita first created a hypothetical TPP based on the technology’s capabilities, which guided commercial, technical and cli

Join for free to read